百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

休市中 11-22 16:08:13

113.800

-3.100

-2.65%

最高117.700	最低112.900	成交量145.93万
今开116.800	昨收116.900	日振幅4.11%
总市值1,569亿	流通市值1,438亿	总股本13.79亿
成交额1.67亿	换手率0.12%	流通股本12.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":113.8,"timestamp":1732262893018,"preClose":116.9,"halted":0,"volume":1459310,"delay":0,"floatShares":1264000000,"shares":1378992949,"eps":-0.6968062,"marketStatus":"休市中","marketStatusCode":7,"change":-3.1,"latestTime":"11-22 16:08:13","open":116.8,"high":117.7,"low":112.9,"amount":167092785,"amplitude":0.041061,"askPrice":113.8,"askSize":9700,"bidPrice":113.7,"bidSize":21900,"shortable":3,"etf":0,"ttmEps":-4.737356931968393,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1533657600000,"adjPreClose":116.9,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0.845443,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":166.43,"timestamp":1732258801000,"preClose":169.28,"halted":0,"volume":2300938,"delay":0,"premium":"-36.24"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2485894312","title":"研报掘金丨招商证券：首予百济神州“强烈推荐”评级，看好短中期泽布替尼等产品的快速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2485894312","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485894312?lang=zh_cn&edition=full","pubTime":"2024-11-22 14:47","pubTimestamp":1732258026,"startTime":"0","endTime":"0","summary":"招商证券研报指出，百济神州是已经完成创新产品全球化销售的国际化药企，其对疾病领域的深刻理解和科学布局是保证持续竞争力的根本。看好百济神州短中期泽布替尼等产品的快速放量，中长期管线产品的竞争力。该行预计百济神州2024-2026年营业收入分别为268.7亿元、338.2亿元、424.6亿元，同比增长54%、26%、26%。首次覆盖，给予“强烈推荐”投资评级。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145158abd6a101&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122145158abd6a101&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"2485864544","title":"港股异动 | 百济神州(06160)盘中涨近3% PRMT5抑制剂国内获批临床 明年将来迎密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2485864544","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485864544?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:56","pubTimestamp":1732157809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州盘中涨近3%，截至发稿，涨2.29%，报120.5港元，成交额1.4亿港元。消息面上，11月19日，据CDE网站显示，百济神州申报的1类新药BGB-58067片获得临床试验默示许可，拟开发治疗晚期实体瘤患者。根据百济神州公开资料，BGB-58067是一款PRMT5抑制剂，为百济神州未来的核心项目之一。根据CDE官网查询，这是该产品首次在中国获批临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0239","BK1161","BK4504","BK4535","BK1583","BK4505","688235","LU1969619763.USD","BGNE","BK1588","06160","BK4139","BK4526","BK4585","BK4548","LU2328871848.SGD","BK1500","BK4588","LU0307460666.USD"],"gpt_icon":0},{"id":"2485102515","title":"百济神州11月20日获南向资金加仓30.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485102515","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485102515?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:30","pubTimestamp":1732152616,"startTime":"0","endTime":"0","summary":"11月20日, 南向资金增持百济神州30.42万股。截止当日收盘，港股通共持有百济神州6307.20万股，占流通股4.54%。百济神州近5个交易日下跌1.01%，港股通累计增持329.09万股；近20个交易日下跌11.96%，港股通累计增持697.73万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2485170656","title":"百济神州：PRMT5抑制剂获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2485170656","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485170656?lang=zh_cn&edition=full","pubTime":"2024-11-21 07:01","pubTimestamp":1732143702,"startTime":"0","endTime":"0","summary":"据不完全统计，当前全球范围内已有10多款PRMT5抑制剂进入到临床试验阶段。根据百济神州公开资料介绍，该公司研发的BGB-58067为第二代MTA协同PRMT5抑制剂，可选择性杀伤MTAP缺失肿瘤细胞，同时避免影响正常血液细胞。据百济神州公开资料介绍，该公司将在2024年推动10个新分子进入临床试验，包括泛KRAS抑制剂、MTA协同PRMT5抑制剂、EGFR降解剂、CDK2抑制剂、ADC和双特异性免疫细胞衔接器等。本次PRMT5抑制剂获批临床，意味着该产品的研发进程迎来重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2484164960","title":"泽布替尼仿制药不得在2037年之前销售，百济神州与MSN达成专利和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2484164960","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484164960?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:05","pubTimestamp":1732093511,"startTime":"0","endTime":"0","summary":"11月19日， 百济神州 宣布已与MSN Pharmaceuticals和MSN Laboratories Private公司达成了和解协议，解决了与MSN在美国提交的Brukinsa 仿制药 注册申请相关的专利诉讼问题。根据协议条款，MSN将无法在2037年6月15日之前销售Brukinsa的仿制药，但在某些惯例情况下，该日期可能会提前或延后。MSN在诉讼中并未对Brukinsa的药物组合专利提出异议，该专利将于2034年4月到期。此前，百济神州与诺华子公司Sandoz已联合提交了一份协议，以撤销针对Sandoz提交的ANDA而提起的专利诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2484138143","title":"百济神州(06160)上涨5.04%，报118.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138143?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:11","pubTimestamp":1732068696,"startTime":"0","endTime":"0","summary":"11月20日，百济神州(06160)盘中上涨5.04%，截至10:11，报118.8元/股，成交7120.85万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2024年三季报，百济神州营业总收入187.97亿元、净利润-34.54亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20101145475695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","BGNE","LU0588546209.SGD","BK1583","BK4588","BK4505","BK4139","BK1588","LU2328871848.SGD","688235","LU1969619763.USD","BK1161","BK0239","BK4548","BK4535","BK4585","BK4504","BK4526","06160","BK1500"],"gpt_icon":0},{"id":"2484138240","title":"百济神州盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138240?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:11","pubTimestamp":1732068689,"startTime":"0","endTime":"0","summary":"2024年11月20日早盘10时11分，百济神州股票出现波动，股价急速拉升5.13%。截至发稿，该股报118.900港元/股，成交量59.21万股，换手率0.05%，振幅6.10%。机构评级方面，在所有32家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为1.24%。该信息摘要如下：东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101129a2473c73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101129a2473c73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1161","688235","LU1969619763.USD","LU0588546209.SGD","BK1500","BK1583","06160","LU0307460666.USD","BK1588"],"gpt_icon":0},{"id":"2484134179","title":"百济神州(06160)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2484134179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484134179?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:01","pubTimestamp":1732010498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，于2024年11月14 日，董事会薪酬委员会根据2016期权及激励计划的条款向3名承授人授出可认购合共3,628股美国存托股份的购股权并向147名承授人授出涉及合共36,689 股美国存托股份的受限制股份单位。购股权行使价为每股美国存托股份201.28美元(约每股普通股120.46港元)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4526","06160","BK4585","LU0588546209.SGD","BK1500","LU1969619763.USD","BK1583","BK0239","BK4548","BK4588","BK4504","BK1588","688235","BK1161","LU2328871848.SGD","BGNE","BK4139","LU0307460666.USD","BK4535"],"gpt_icon":0},{"id":"2484930963","title":"百济神州11月18日获南向资金加仓93.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484930963","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484930963?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:30","pubTimestamp":1731979817,"startTime":"0","endTime":"0","summary":"11月18日, 南向资金增持百济神州93.55万股。截止当日收盘，港股通共持有百济神州6234.40万股，占流通股4.49%。百济神州近5个交易日下跌10.46%，港股通累计增持294.31万股；近20个交易日下跌14.95%，港股通累计增持744.48万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4535","688235","BK4504","BGNE","BK4588","06160","BK4139","BK4505","BK4526","BK4548"],"gpt_icon":0},{"id":"2484949934","title":"百济神州（688235）11月18日主力资金净卖出6032.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484949934","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484949934?lang=zh_cn&edition=full","pubTime":"2024-11-19 08:26","pubTimestamp":1731976002,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月18日收盘，百济神州报收于156.21元，下跌5.51%，换手率3.45%，成交量3.97万手，成交额6.34亿元。近5日资金流向一览见下表：百济神州融资融券信息显示，融资方面，当日融资买入4279.99万元，融资偿还6022.09万元，融资净偿还1742.1万元。百济神州主营业务：研究、开发、生产以及商业化创新型药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900007237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","LU0588546209.SGD","BK1588","LU2328871848.SGD","BK1583","06160","LU1969619763.USD","688235","BK1161","LU0307460666.USD","BK0239"],"gpt_icon":0},{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4087","BK4526","688235","BK4504","LU0053666078.USD","BK4535","BK4505","BK4548","BK4107","BK4585","L","06160","CHMP","BGNE"],"gpt_icon":0},{"id":"2484617046","title":"11月18日百济神州-U跌5.51%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484617046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484617046?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:12","pubTimestamp":1731917526,"startTime":"0","endTime":"0","summary":"证券之星消息，11月18日百济神州-U跌5.51%，收盘报156.21元，换手率3.45%，成交量3.97万手，成交额6.34亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800019693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","160916","BK1588","06160","LU0588546209.SGD","LU2328871848.SGD","688235","BK1500","LU1969619763.USD","BK0239","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2484617601","title":"东吴证券：百济神州成长确定性较高，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484617601","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484617601?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:51","pubTimestamp":1731916297,"startTime":"0","endTime":"0","summary":"东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。Q3 总收入达10.02亿美元，2024Q1-Q3 收入分别为7.5/9.3/10.0亿美元，欧美市场贡献超76%。截至前三季度，GAAP净亏损1.21亿美元，业绩符合的预期。考虑到公司核心产品销售额持续高速增长，维持公司2024/2025/2026 年营业收入为255.3亿元、340.6亿元和423.8亿元的预测。公司催化剂不断兑现，海外市场进一步打开，成长确定性较高，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160034a2424532&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160034a2424532&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"2484614360","title":"《大行》交银国际升百济神州(06160.HK)目标价至159元  催化剂即将密集落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614360","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614360?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:33","pubTimestamp":1731915180,"startTime":"0","endTime":"0","summary":"交银国际发表报告指，百济神州第三季产品销售放量趋势不改，泽布替尼核心适应症新患份额持续扩大：公司总收入按年增长28.2%至10.02亿美元。经调整non-GAAP经营利润为6,563万美元，连续两个季度实现non-GAAP经营利润转正。该行上调百济神州H股目标价至159港元。沽空资料截至 2024-11-18 12:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20181116161836565_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20181116161836565_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397482/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688235","06160"],"gpt_icon":0},{"id":"2484861488","title":"《大行》招银国际降百济神州(BGNE.US)目标价至276.02美元  non-GAAP利润持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2484861488","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484861488?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:06","pubTimestamp":1731913560,"startTime":"0","endTime":"0","summary":"招银国际发表报告指出，百济神州第三季产品销售9.93亿美元，按季升8%，按年升67%。季内，百济神州从营运中产生1.88亿美元的正向现金流入。凭借其强劲的销售势头及不断改善的经营利润率，该行料百济神州将于2025财年实现收支平衡。此外，该行维持对百济神州美股的“买入”评级，目标价由288.93美元下调至276.02美元，认为公司仍是其首选。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240724105052352_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240724105052352_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397479/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06160","688235"],"gpt_icon":0},{"id":"2484619053","title":"《大行》招商证券升百济神州(BGNE.US)目标价至376美元  百悦泽海外收入保持快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2484619053","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484619053?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:55","pubTimestamp":1731912900,"startTime":"0","endTime":"0","summary":"招商证券国际发表报告，上调对百济神州(BGNE.US)  ADR目标价，由345美元升至376美元，维持“增持”评级。该行指，公司第三季产品收入按年升67%至9.93亿美元，主要反映百悦泽在全球持续取得商业化成功，销售按年升93%至6.9亿美元。该行上调对百悦泽明年收入预测至32亿美元，相当于按年升24%，主要基于百悦泽较亿珂在慢淋中显示优效性，美国临床医生和保险支付方的接受度持续提高。该行料百悦泽明年美销售可望超过20亿美元，其他海外地区有望超过7.2亿美元，分别按年升逾两成及逾52%。(fc/da)(美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20181116161835808_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20181116161835808_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397473/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688235","06099","06160"],"gpt_icon":0},{"id":"2484693949","title":"创新药龙头百济神州：造血能力不足三季报续亏，“烧钱模式”不休","url":"https://stock-news.laohu8.com/highlight/detail?id=2484693949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484693949?lang=zh_cn&edition=full","pubTime":"2024-11-18 11:13","pubTimestamp":1731899604,"startTime":"0","endTime":"0","summary":"11月13日-15日，创新药龙头百济神州股价持续阴跌，这背后或源于三季报成绩单不能让投资者满意。而2017年至今，百济神州长期处于“失血”状态，累计亏近580亿元。财报显示，今年前三季度百济神州实现营业收入191.36亿元，同比增长48.6%。对于最晚获批的百汇泽，百济神州在三季报中没有提及。百济神州前三季度的研发费用支出为101.66亿元，较上年同期有所增长。经计算，百济神州7年零9个月期间累计亏损近580亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024111800008242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1500","BK0239","LU0307460666.USD","LU2328871848.SGD","BK1161","BK1583","LU1969619763.USD","BK1588","06160","159992","688235","LU0588546209.SGD","BK1574"],"gpt_icon":0},{"id":"2484684935","title":"百济神州拟用4.9亿超募资金补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2484684935","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484684935?lang=zh_cn&edition=full","pubTime":"2024-11-17 19:08","pubTimestamp":1731841722,"startTime":"0","endTime":"0","summary":"财中社11月17日电百济神州（688235/06160/BGNE）发布关于使用部分超募资金永久补充流动资金的公告。公司董事会于2024年11月12日审议通过，决定使用超募资金4.9亿元用于永久补充流动资金，此次补流将不超过超募资金总额的30%。公司承诺在补流后的十二个月内不进行高风险投资，也不会为除全资、控股子公司以外的第三方提供财务资助。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241787951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1500","LU2328871848.SGD","BK4504","BK4548","BK4505","BK1588","06160","BK4526","BK4585","BK1161","BK1583","LU0307460666.USD","LU1969619763.USD","BK4535","LU0588546209.SGD","BGNE","BK4588"],"gpt_icon":0},{"id":"2484868942","title":"东吴证券：给予百济神州买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484868942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484868942?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:40","pubTimestamp":1731840027,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对百济神州进行研究并发布了研究报告《2024年三季报点评：海外销售快速放量，血液瘤行业领先》，本报告对百济神州给出买入评级，当前股价为165.32元。公司催化剂不断兑现，海外市场进一步打开，成长确定性较高，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为200.12。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111700001470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160","601555"],"gpt_icon":0},{"id":"2484815436","title":"东吴证券给予百济神州买入评级，2024年三季报点评：海外销售快速放量，血液瘤行业领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2484815436","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484815436?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:37","pubTimestamp":1731839865,"startTime":"0","endTime":"0","summary":"东吴证券11月17日发布研报称，给予百济神州（688235.SH，最新价：165.32元）买入评级。评级理由主要包括：1）事件：销售收入快速增长，经营性现金流转正；2）BTKi领域领导者，BCL2i和BTKCDAC奠定血液瘤龙头地位；3）以替雷利珠单抗为核心，拓展实体瘤新分子。风险提示：销售收入不及预期；海外注册开发失败；和艾伯维的专利纠纷等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411173241784748.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241784748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","BGNE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1495},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.241},{"period":"1year","weight":0.0026},{"period":"ytd","weight":0.0336}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"　　百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.03281},{"month":2,"riseRate":0.5,"avgChangeRate":0.020001},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.060772},{"month":4,"riseRate":0.5,"avgChangeRate":0.051983},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.053583},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.428571,"avgChangeRate":0.102864},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.054912}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}